NICE supports Roche's ALK inhibitor Rozlytrek to treat ROS1-positive non-small cell lung cancer patients

NICE UK has published a draft final guidelines to support the NHS's use of Roche's ALK inhibitor Rozlytinib for patients with advanced non-small cell lung cancer (
NSCLC) who have not previously been treated with ROS1 inhibitorsROS1 is a rare mutation found in less than 2% of NSCLC cases and there is currently no therapeutic option, especially in patients whose disease has spread to the brainNICE noted that in clinical trials, Rozlytrek has been shown to be effective in reducing tumors and suppressing overall progression of the disease (the median is 16.8 months without progress), including patients with brain metastasisthe drug also meets NICE standards and is considered a life-extending treatment because there is evidence that it can extend life by more than three months compared to permeycere combined with platinum chemotherapy (NSCLC standard treatment)Karen Lightning-Jones, head of personalized medicine and strategic collaboration at Roche, said NICE's recognition was "an important milestone for patients with ROS1-positive, limited treatment options."it is estimated that the treatment will be used in 412 people in the UK